Antibody and Vaccine Group, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Front Immunol. 2023 Apr 25;14:1147467. doi: 10.3389/fimmu.2023.1147467. eCollection 2023.
The tumor necrosis factor superfamily (TNFSF) and their receptors (TNFRSF) are important regulators of the immune system, mediating proliferation, survival, differentiation, and function of immune cells. As a result, their targeting for immunotherapy is attractive, although to date, under-exploited. In this review we discuss the importance of co-stimulatory members of the TNFRSF in optimal immune response generation, the rationale behind targeting these receptors for immunotherapy, the success of targeting them in pre-clinical studies and the challenges in translating this success into the clinic. The efficacy and limitations of the currently available agents are discussed alongside the development of next generation immunostimulatory agents designed to overcome current issues, and capitalize on this receptor class to deliver potent, durable and safe drugs for patients.
肿瘤坏死因子超家族（TNFSF）及其受体（TNFRSF）是免疫系统的重要调节剂，介导免疫细胞的增殖、存活、分化和功能。因此，针对它们的免疫治疗具有吸引力，尽管迄今为止利用不足。在这篇综述中，我们讨论了 TNFRSF 的共刺激成员在产生最佳免疫反应中的重要性、针对这些受体进行免疫治疗的原理、在临床前研究中靶向这些受体的成功以及将这一成功转化为临床的挑战。讨论了当前可用药物的疗效和局限性，以及开发旨在克服当前问题并利用这一受体类别的下一代免疫刺激药物，为患者提供有效、持久和安全的药物。
